Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation
• By Aidan Fry
Hikma is looking to bring anaphylaxis treatment epinephrine and the opioid overdose drug naloxone to the US market as unit-dose nasal sprays • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
